Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Medicine & Life Sciences

• Imatinib Mesylate 100%
• Type 1 Diabetes Mellitus 78%
• Placebos 60%
• C-Peptide 26%
• Therapeutics 14%
• Intention to Treat Analysis 13%
• Meals 10%
• Safety 10%
• Area Under Curve 9%
• faropenem medoxomil 8%
• Metabolic Networks and Pathways 5%
• Pharmacists 5%
• Random Allocation 5%
• Duration of Therapy 5%
• Autoantibodies 5%
• Tablets 5%
• Protein-Tyrosine Kinases 5%
• Nausea 5%
• Pharmaceutical Preparations 4%
• Occupational Groups 4%
• Observation 4%
• Child 2%